"It looks like there are a lot of practices that are reticent about employing same-day discharge," says Brian R. Lane, MD, PhD, FACS.
In this video, Brian R. Lane, MD, PhD, FACS, shares the take-home message from the recent Urology Practice paper, “Uptake of Same-Day Discharge for Patients Undergoing Robot-Assisted Radical Prostatectomy in the Michigan Urological Surgery Improvement Collaborative.” Lane is program director of MUSIC – KIDNEY. research director of urologic oncology at Corewell Health Cancer Center, and professor at Michigan State University College of Human Medicine.
It looks like there are a lot of practices that are reticent about employing same-day discharge. And I can imagine there's a variety of reasons why. It's a different process. Nursing staff in the postoperative area or on the urology floor needs to reorient their education to the patient. They have to do it all at one time, vs being able to do catheter training maybe the next day after surgery. The clinic offices need to be clued into the fact that patients are going to be home and they might be getting calls on that first day. So there are reasons that I can understand that a group wouldn't be excited about implementing it, but it really looks like from our evaluation of the data in the state of Michigan, there's not an increase in emergency department or readmissions for patients that have undergone same-day discharge. It really doesn't look like there are a lot of downsides. It just needs to be implemented well at each practice. So I think this paper could be practice changing in really asking each practice, could you implement it? I think education of the patients and streamlined plans of care after surgery are really the key things, and with those in place, I think a number of practices would be able to safely implement same-day discharge.
This transcription was edited for clarity.
Olaparib monotherapy shows benefit in HRR+ biochemically recurrent prostate cancer
August 22nd 2024“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.